AVC

LOE Approaching

sulfanilamide

NDAVAGINALCREAM
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Clinical Trials (5)

NCT06635148Phase 2Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Started Sep 2024
274 enrolled
Geographic AtrophyMacular Degeneration
NCT05811351Phase 2Completed

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Started Mar 2023
305 enrolled
Geographic Atrophy
NCT03585556Phase 1Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Started Sep 2018
25 enrolled
Wet Age-related Macular Degeneration
NCT03144999Phase 1Completed

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

Started Mar 2017
17 enrolled
Dry Age-related Macular Degeneration
NCT02610400Phase 3Completed

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

Started Feb 2016
9,845 enrolled
Malaria